Argus raised the firm’s price target on Quest Diagnostics (DGX) to $175 from $163 and keeps a Buy rating on the shares. The company reported strong Q3 results, reflecting higher healthcare utilization, acquisitions and solid execution, the analyst tells investors in a research note. The firm says the company is driving growth from acquisitions and from its organic business and is on track to complete eight acquisitions in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $174 from $160 at Mizuho
- Snap upgraded, McDonald’s downgraded: Wall Street’s top analyst calls
- Quest Diagnostics awarded several contracts by CDC
- Quest Diagnostics price target raised to $185 from $165 at Citi
- Quest Diagnostics price target raised to $168 from $154 at Barclays